CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Usefulness of minimum stent cross sectional area as a predictor of angiographic restenosis after primary percutaneous coronary intervention in acute myocardial infarction (from the HORIZONS-AMI Trial IVUS substudy) Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Novel predictors of late lumen enlargement in distal reference segments after successful recanalization of coronary chronic total occlusion The Year in Cardiovascular Medicine 2020: Imaging: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of imaging are Fausto Pinto, José Luis Zamorano and Chiara Bucciarelli-Ducci. Judy Ozkan speaks with them Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Sex differences in left main coronary artery stenting: Different characteristics but similar outcomes for women compared with men Accuracy of Fractional Flow Reserve Derived From Coronary Angiography Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week

Recommandation StatementVolume 8, Issue 1, January 2020

JOURNAL:JACC Heart Fail. Article Link

The Hospital Readmissions Reduction Program Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper

MA Psotka, GC Fonarow, LA Allen et al. Keywords: 30-day readmission; heart failure; HRRP; Medicare

ABSTRACT


The mandatory federal pay-for-performance Hospital Readmissions Reduction Program (HRRP) was created to decrease 30-day hospital readmissions by instituting accountability and stimulating quality care and coordination, particularly during care transitions. The HRRP has changed the landscape of hospital readmissions and reimbursement within the United States by imposing substantial Medicare payment penalties on hospitals with higher-than-expected readmission rates. However, the HRRP has been controversial since its inception, particularly in the field of heart failure. Proponents argue that it has reduced national readmission rates, in part by raising awareness and investment in mechanisms to better assist patients during discharge and transitions; opponents contend that it unfairly penalizes hospitals for issues beyond their control, has unintended negative consequences due to incentivizing readmission over survival, that it encourages “gaming” the system, was not tested before implementation, and that it does not specify how hospitals can improve their performance. This paper incorporates the diverse, nuanced, and sometimes divergent interpretations presented during a multifaceted expert clinician discussion regarding the HRRP and heart failure; in cases in which consensus opinions were achieved, they are presented, including regarding potential new iterations of the HRRP for the future. Potential improvements include more comprehensive incorporation of outcomes into the HRRP measure and better risk adjustment to improve equality and fairness.